Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August3, 2017, Inotek Pharmaceuticals Corporation announced its financial results for the quarter ended June30, 2017. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 2.02 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
| 99.1 | Press release issued by Inotek Pharmaceuticals Corporation on August3, 2017, furnished herewith. |
INOTEK PHARMACEUTICALS CORP ExhibitEX-99.1 2 d434045dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights LEXINGTON,…To view the full exhibit click here
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.
